813 related articles for article (PubMed ID: 27094609)
21. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer.
Foidart JM; Schaaps JP; Chantraine F; Munaut C; Lorquet S
J Reprod Immunol; 2009 Nov; 82(2):106-11. PubMed ID: 19853925
[TBL] [Abstract][Full Text] [Related]
22. Eclampsia in the 21st century.
Fishel Bartal M; Sibai BM
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1237-S1253. PubMed ID: 32980358
[TBL] [Abstract][Full Text] [Related]
23. Preeclampsia: Pathophysiology and management.
Nirupama R; Divyashree S; Janhavi P; Muthukumar SP; Ravindra PV
J Gynecol Obstet Hum Reprod; 2021 Feb; 50(2):101975. PubMed ID: 33171282
[TBL] [Abstract][Full Text] [Related]
24. Soluble endoglin contributes to the pathogenesis of preeclampsia.
Venkatesha S; Toporsian M; Lam C; Hanai J; Mammoto T; Kim YM; Bdolah Y; Lim KH; Yuan HT; Libermann TA; Stillman IE; Roberts D; D'Amore PA; Epstein FH; Sellke FW; Romero R; Sukhatme VP; Letarte M; Karumanchi SA
Nat Med; 2006 Jun; 12(6):642-9. PubMed ID: 16751767
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin receptors, autoimmunity, and preeclampsia.
Xia Y; Zhou CC; Ramin SM; Kellems RE
J Immunol; 2007 Sep; 179(6):3391-5. PubMed ID: 17785770
[TBL] [Abstract][Full Text] [Related]
26. Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy.
Karumanchi SA
Hypertension; 2016 Jun; 67(6):1072-9. PubMed ID: 27067718
[No Abstract] [Full Text] [Related]
27. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
[TBL] [Abstract][Full Text] [Related]
28. The Role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia.
Campbell N; LaMarca B; Cunningham MW
Curr Pharm Biotechnol; 2018; 19(10):781-785. PubMed ID: 30255752
[TBL] [Abstract][Full Text] [Related]
29. Preeclampsia: an update.
Lambert G; Brichant JF; Hartstein G; Bonhomme V; Dewandre PY
Acta Anaesthesiol Belg; 2014; 65(4):137-49. PubMed ID: 25622379
[TBL] [Abstract][Full Text] [Related]
30. Angiogenic factors and preeclampsia.
Tjoa ML; Levine RJ; Karumanchi SA
Front Biosci; 2007 Jan; 12():2395-402. PubMed ID: 17127249
[TBL] [Abstract][Full Text] [Related]
31. Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia.
Nissaisorakarn P; Sharif S; Jim B
Curr Cardiol Rep; 2016 Dec; 18(12):131. PubMed ID: 27837384
[TBL] [Abstract][Full Text] [Related]
32. Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension.
Scott G; Gillon TE; Pels A; von Dadelszen P; Magee LA
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1222-S1236. PubMed ID: 32828743
[TBL] [Abstract][Full Text] [Related]
33. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia.
Onda K; Tong S; Nakahara A; Kondo M; Monchusho H; Hirano T; Kaitu'u-Lino T; Beard S; Binder N; Tuohey L; Brownfoot F; Hannan NJ
Hypertension; 2015 Apr; 65(4):855-62. PubMed ID: 25667213
[TBL] [Abstract][Full Text] [Related]
34. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia.
Silasi M; Cohen B; Karumanchi SA; Rana S
Obstet Gynecol Clin North Am; 2010 Jun; 37(2):239-53. PubMed ID: 20685551
[TBL] [Abstract][Full Text] [Related]
35. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia.
Zhou CC; Irani RA; Zhang Y; Blackwell SC; Mi T; Wen J; Shelat H; Geng YJ; Ramin SM; Kellems RE; Xia Y
Circulation; 2010 Jan; 121(3):436-44. PubMed ID: 20065159
[TBL] [Abstract][Full Text] [Related]
36. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.
Rana S; Burke SD; Karumanchi SA
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1019-S1034. PubMed ID: 33096092
[TBL] [Abstract][Full Text] [Related]
37. Molecular hydrogen ameliorates several characteristics of preeclampsia in the Reduced Uterine Perfusion Pressure (RUPP) rat model.
Ushida T; Kotani T; Tsuda H; Imai K; Nakano T; Hirako S; Ito Y; Li H; Mano Y; Wang J; Miki R; Yamamoto E; Iwase A; Bando YK; Hirayama M; Ohno K; Toyokuni S; Kikkawa F
Free Radic Biol Med; 2016 Dec; 101():524-533. PubMed ID: 27789293
[TBL] [Abstract][Full Text] [Related]
38. Serum amyloid A1 and pregnancy zone protein in pregnancy complications and correlation with markers of placental dysfunction.
Fosheim IK; Jacobsen DP; Sugulle M; Alnaes-Katjavivi P; Fjeldstad HES; Ueland T; Lekva T; Staff AC
Am J Obstet Gynecol MFM; 2023 Jan; 5(1):100794. PubMed ID: 36334725
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of preeclampsia.
Sircar M; Thadhani R; Karumanchi SA
Curr Opin Nephrol Hypertens; 2015 Mar; 24(2):131-8. PubMed ID: 25636145
[TBL] [Abstract][Full Text] [Related]
40. Usefulness of the sFlt-1/PlGF (Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor) Ratio in Diagnosis or Misdiagnosis in Women With Clinical Diagnosis of Preeclampsia.
Leaños-Miranda A; Graciela Nolasco-Leaños A; Ismael Carrillo-Juárez R; José Molina-Pérez C; Janet Sillas-Pardo L; Manuel Jiménez-Trejo L; Isordia-Salas I; Leticia Ramírez-Valenzuela K
Hypertension; 2020 Sep; 76(3):892-900. PubMed ID: 32713272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
